Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting.
Quiver AI Summary
Erasca, Inc. presented new preclinical data at the American Association for Cancer Research Annual Meeting, showcasing their RAS-targeting compounds, ERAS-0015 and ERAS-4001, which demonstrated strong anti-tumor activity both as monotherapy and in combination therapies. ERAS-0015 is highlighted as a pan-RAS molecular glue with superior pharmacokinetic properties compared to competitor drugs, potentially allowing effective treatment of RAS mutant solid tumors at lower doses. Meanwhile, ERAS-4001, a pan-KRAS inhibitor, selectively targets both mutant and wildtype KRAS, potentially overcoming resistance in cancer therapies. Additionally, the company identified new SHOC2 binders which may provide a novel approach to inhibit RAS/MAPK signaling. Erasca aims to advance these compounds into clinical development within the year, focusing on innovative therapies for cancers driven by the RAS/MAPK pathway.
Potential Positives
- ERAS-0015 and ERAS-4001 demonstrated robust anti-tumor activity, highlighting the potential effectiveness of Erasca's RAS-targeting therapies at the AACR Annual Meeting.
- The identification of first-in-class direct SHOC2 binders may represent a new approach to inhibit oncogenic RAS/MAPK signaling, positioning Erasca at the forefront of innovation in cancer treatment.
- Research presented indicates favorable pharmacokinetic properties of ERAS-0015, allowing for effective anti-tumor activity at significantly lower doses compared to current leading treatments.
- ERAS-4001 showcases a potentially expanded therapeutic index by selectively targeting key KRAS mutations, addressing resistance mechanisms seen with other KRAS inhibitors.
Potential Negatives
- Statements in the press release are characterized as forward-looking, indicating potential risks and uncertainties regarding the success of the company's product candidates, specifically ERAS-0015 and ERAS-4001, which may not be predictive of future results.
- The cautionary note highlights significant risks including potential delays in clinical trials and dependence on third parties, which could impact the company's ability to successfully advance its therapies.
- The mention of a novel and unproven approach to shutting down the RAS/MAPK pathway underscores the experimental nature of their products and the inherent risks associated with such strategies in oncology.
FAQ
What are ERAS-0015 and ERAS-4001?
ERAS-0015 is a pan-RAS molecular glue, and ERAS-4001 is a pan-KRAS inhibitor designed for cancer therapies.
How do ERAS-0015 and ERAS-4001 work?
Both compounds target the RAS/MAPK pathway to inhibit tumor growth, with ERAS-0015 specifically engaging RAS in its active state.
What results were presented at the AACR meeting?
Preclinical data showed robust anti-tumor activities for both ERAS-0015 and ERAS-4001, highlighting their best-in-class potential.
What is the significance of SHOC2 binders?
SHOC2 binders represent a novel approach to block RAS/MAPK signaling, potentially addressing resistance mechanisms in RAS-driven cancers.
When will clinical development for these compounds begin?
Erasca aims to initiate the clinical development of ERAS-0015 and ERAS-4001 within this year.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ERAS Hedge Fund Activity
We have seen 79 institutional investors add shares of $ERAS stock to their portfolio, and 53 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OCTAGON CAPITAL ADVISORS LP added 5,136,795 shares (+inf%) to their portfolio in Q4 2024, for an estimated $12,893,355
- JANUS HENDERSON GROUP PLC removed 4,036,348 shares (-98.2%) from their portfolio in Q4 2024, for an estimated $10,131,233
- BANK OF AMERICA CORP /DE/ removed 2,274,898 shares (-53.9%) from their portfolio in Q4 2024, for an estimated $5,709,993
- MILLENNIUM MANAGEMENT LLC added 1,767,350 shares (+73.3%) to their portfolio in Q4 2024, for an estimated $4,436,048
- LOGOS GLOBAL MANAGEMENT LP added 1,600,000 shares (+14.7%) to their portfolio in Q4 2024, for an estimated $4,015,999
- SUVRETTA CAPITAL MANAGEMENT, LLC removed 1,453,035 shares (-10.6%) from their portfolio in Q4 2024, for an estimated $3,647,117
- PROSIGHT MANAGEMENT, LP removed 1,036,900 shares (-52.3%) from their portfolio in Q4 2024, for an estimated $2,602,619
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ERAS Analyst Ratings
Wall Street analysts have issued reports on $ERAS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 11/18/2024
To track analyst ratings and price targets for $ERAS, check out Quiver Quantitative's $ERAS forecast page.
$ERAS Price Targets
Multiple analysts have issued price targets for $ERAS recently. We have seen 2 analysts offer price targets for $ERAS in the last 6 months, with a median target of $5.5.
Here are some recent targets:
- Laura Prendergast from Raymond James set a target price of $5.0 on 03/26/2025
- Maury Raycroft from Jefferies set a target price of $6.0 on 11/18/2024
Full Release
ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy
First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today presented new preclinical data reinforcing the best-in-class profiles of Erasca’s RAS-targeting franchise at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. The Company also presented potential first-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly, representing a new approach to block oncogenic RAS/MAPK pathway signaling. The posters are available online at
Erasca.com/science/#presentations
.
“We were pleased to present new preclinical data at this year’s AACR meeting further solidifying our understanding of the properties that support the best-in-class potential of our pan-RAS molecular glue ERAS-0015 and the best-in-class/first-in-class potential of our pan-KRAS inhibitor ERAS-4001. We also showcased our research capabilities with, to our knowledge, the first identification of direct SHOC2 binders targeting the RAS/MAPK pathway in collaboration with our scientific advisory board member Pablo Rodriguez-Viciana,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Importantly, these data reinforce the favorable pharmacokinetic properties that allow for robust anti-tumor activity at significantly lower doses of ERAS-0015 versus the leading pan-RAS molecular glue in development, as well as the potential expanded therapeutic index of ERAS-4001 through selective targeting of key KRAS mutations. We are excited to achieve our goal of advancing development of both RAS-targeting compounds in the clinic this year.”
Poster Presentation Highlights
Abstract 390 – ERAS-0015 is a pan-RAS molecular glue with best-in-class potential in RAS mutant solid tumors
ERAS-0015 demonstrated favorable pharmacokinetic properties including longer residence time and greater tissue exposure that led to robust anti-tumor activity alone and in combination at doses lower than the leading pan-RAS molecular glue in development.
ERAS-0015 is a pan-RAS molecular glue designed to shut down pathogenic signaling mediated by mutant and wildtype RAS by targeting RAS in the GTP-bound state.
8-21-fold greater cyclophilin A (CypA) binding for ERAS-0015 vs. pan-RAS molecular glue comparator RMC-6236
ERAS-0015 dose-dependently formed a ternary complex with active state RAS and CypA, which blocks formation of additional downstream effector complexes
Potent inhibition of proliferation with ERAS-0015 across a panel of cell lines spanning diverse tumor tissues and RAS mutations
Preferential drug distribution into tumor tissues
Promising monotherapy and combination activity across multiple RAS mutant models
ERAS-4001 potentially has an expanded therapeutic index relative to pan-RAS inhibitors by selectively targeting both mutant and wildtype KRAS, leading to significant tumor growth inhibition alone and in combination.
Selectively targeting both wildtype (WT) and oncogenic KRAS may address resistance mechanisms to mutant-selective KRAS inhibitors that are driven by WT KRAS activity. A potential first-in-class pan-KRAS inhibitor, ERAS-4001 is a novel, highly potent pan-KRAS inhibitor that blocks mutant and WT KRAS, potentially offering improved tolerability relative to pan-RAS inhibitors by sparing NRAS and HRAS.
ERAS-4001 selectively inhibited KRAS mutant enzymes and WT KRAS over WT HRAS and NRAS
ERAS-4001 inhibited 3D cell viability and proliferation in 13 G12X mutant and one wildtype KRAS amplified cell lines across indications with single digit nanomolar IC50s
Dose-dependent tumor growth inhibition and significant antitumor efficacy with ERAS-4001 monotherapy in KRAS mutant xenograft models
Robust tumor growth inhibition with ERAS-4001 plus anti-PD-1 or cetuximab in KRAS mutant models
Promising antitumor monotherapy and combination activity across multiple KRAS mutant models
Abstract 3152 – Identification and characterization of inhibitors of SHOC2-MRAS-PP1C complex assembly
Identified inhibitors of SMP complex assembly via SHOC2 engagement, representing a potential new approach to attenuate RAS/MAPK pathway signaling.
Genetic ablation or protein degradation of SHOC2 can sensitize RAS-driven cells to RAS/MAPK pathway inhibitors and prevent adaptive resistance.
Identified two lead series that bind selectively to SHOC2 with low nanomolar affinity, interfere with SMP complex assembly, and inhibit the SMP complex’s phosphatase activity
To our knowledge, these compounds represent the first examples of direct modulators of the SMP complex
Further optimization of SHOC2 binders for protein-protein inhibitors (PPIs) and degrader modalities is ongoing
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipelines in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Cautionary Note Regarding Forward-Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the potential therapeutic benefits of our product candidates and early-stage development projects, including ERAS-0015, ERAS-4001, and our SHOC2 binding project; and our ability to achieve our goal of initiating the clinical development of ERAS-0015 and ERAS-4001 this year. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our approach to the development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; results from preclinical studies not necessarily being predictive of future results; our assumptions around which programs may have a higher probability of success may not be accurate, and we may expend our limited resources to pursue a particular product candidate and/or indication and fail to capitalize on product candidates or indications with greater development or commercial potential; potential delays in the commencement, enrollment, and completion of clinical trials and preclinical studies; our dependence on third parties in connection with manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims; unfavorable results from preclinical studies or clinical trials; the inability to realize any benefits from our current licenses, acquisitions, and collaborations, and any future licenses, acquisitions, or collaborations, and our ability to fulfill our obligations under such arrangements; regulatory developments in the United States and foreign countries; our ability to fund our operating plans with our current cash, cash equivalents, and marketable securities; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
